Page 118 - Read Online

Offin et al. J Cancer Metastasis Treat 2023;9:21 https://dx.doi.org/10.20517/2394-4722.2022.140 Page 15 of 16

DOI PubMed PMC
83. Zauderer MG, Szlosarek PW, Le Moulec S, et al. EZH2 inhibitor tazemetostat in patients with relapsed or refractory, BAP1-
inactivated malignant pleural mesothelioma: a multicentre, open-label, phase 2 study. Lancet Oncol 2022;23:758-67. DOI PubMed
84. Lakhani NJ, Gutierrez M, Duska LR, et al. Phase 1/2 first-in-human (FIH) study of CPI-0209, a novel small molecule inhibitor of
enhancer of zeste homolog 2 (EZH2) in patients with advanced tumors. JCO 2021;39:3104-3104. DOI
85. Fennell DA, King A, Mohammed S, et al. Rucaparib in patients with BAP1-deficient or BRCA1-deficient mesothelioma (MiST1): an
open-label, single-arm, phase 2a clinical trial. Lancet Respir Med 2021;9:593-600. DOI PubMed
86. Ghafoor A, Mian I, Wagner C, et al. Phase 2 study of olaparib in malignant mesothelioma and correlation of efficacy with germline
or somatic mutations in BAP1 gene. JTO Clin Res Rep 2021;2:100231. DOI PubMed PMC
87. Koczywas M. Phase I study of TRC102 in combination with cisplatin and pemetrexed in patients with advanced solid tumors/Phase II
study of TRC102 with pemetrexed in patients with mesothelioma refractory to pemetrexed and cisplatin or carboplatin. In: ASCO
Virtual Scientific Program: American Society of Clinical Oncology; 2020.
88. Passiglia F, Bironzo P, Righi L, et al. A prospective phase II single-arm study of niraparib plus dostarlimab in patients with advanced
non-small-cell lung cancer and/or malignant pleural mesothelioma, positive for PD-L1 expression and germline or somatic mutations
in the DNA repair genes: rationale and study design. Clin Lung Cancer 2021;22:e63-6. DOI PubMed
89. Gounder M, Schöffski P, Jones RL, et al. Tazemetostat in advanced epithelioid sarcoma with loss of INI1/SMARCB1: an
international, open-label, phase 2 basket study. Lancet Oncol 2020;21:1423-32. DOI
90. Morschhauser F, Tilly H, Chaidos A, et al. Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label,
single-arm, multicentre, phase 2 trial. Lancet Oncol 2020;21:1433-42. DOI PubMed PMC
91. Moore K, Colombo N, Scambia G, et al. Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer. N Engl J
Med 2018;379:2495-505. DOI
92. Pujade-Lauraine E, Ledermann JA, Selle F, et al. Olaparib tablets as maintenance therapy in patients with platinum-sensitive,
relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3
trial. Lancet Oncol 2017;18:1274-84. DOI PubMed
93. Robson M, Im SA, Senkus E, et al. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N Engl J Med
2017;377:523-33. DOI
94. Carter RJ, Parsons JL. Base excision repair, a pathway regulated by posttranslational modifications. Mol Cell Biol 2016;36:1426-37.
DOI PubMed PMC
95. Mundlos S, Pelletier J, Darveau A, Bachmann M, Winterpacht A, Zabel B. Nuclear localization of the protein encoded by the Wilms’
tumor gene WT1 in embryonic and adult tissues. Development 1993;119:1329-41. DOI PubMed
96. Foster MR, Johnson JE, Olson SJ, Allred DC. Immunohistochemical analysis of nuclear versus cytoplasmic staining of WT1 in
malignant mesotheliomas and primary pulmonary adenocarcinomas. Arch Pathol Lab Med 2001;125:1316-20. DOI PubMed
97. Oates J, Edwards C. HBME-1, MOC-31, WT1 and calretinin: an assessment of recently described markers for mesothelioma and
adenocarcinoma. Histopathology 2000;36:341-7. DOI PubMed
98. Ordóñez NG. The immunohistochemical diagnosis of mesothelioma: a comparative study of epithelioid mesothelioma and lung
adenocarcinoma. Am J Surg Pathol 2003;27:1031-51. DOI PubMed
99. Zauderer MG, Tsao AS, Dao T, et al. A randomized phase II trial of adjuvant galinpepimut-S, WT-1 analogue peptide vaccine, after
multimodality therapy for patients with malignant pleural mesothelioma. Clin Cancer Res 2017;23:7483-9. DOI PubMed PMC
100. Sekido Y, Pass HI, Bader S, Mew DJ, Christman MF, Gazdar AF et al. Neurofibromatosis type 2 (NF2) gene is somatically mutated
in mesothelioma but not in lung cancer. Cancer Res 1995;55:1227-31. PubMed
101. Bianchi AB, Mitsunaga SI, Cheng JQ, et al. High frequency of inactivating mutations in the neurofibromatosis type 2 gene (NF2) in
primary malignant mesotheliomas. Proc Natl Acad Sci USA 1995;92:10854-8. DOI PubMed PMC
102. Ladanyi M, Zauderer MG, Krug LM, et al. New strategies in pleural mesothelioma: BAP1 and NF2 as novel targets for therapeutic
development and risk assessment. Clin Cancer Res 2012;18:4485-90. DOI PubMed PMC
103. Okada M, Kijima T, Aoe K, et al. Clinical efficacy and safety of nivolumab: results of a multicenter, open-label, single-arm, japanese
phase II study in Malignant pleural mesothelioma (MERIT). Clin Cancer Res 2019;25:5485-92. DOI PubMed
104. Poulikakos PI, Xiao GH, Gallagher R, Jablonski S, Jhanwar SC, Testa JR. Re-expression of the tumor suppressor NF2/merlin inhibits
invasiveness in mesothelioma cells and negatively regulates FAK. Oncogene 2006;25:5960-8. DOI PubMed
105. Shapiro IM, Kolev VN, Vidal CM, et al. Merlin deficiency predicts FAK inhibitor sensitivity: a synthetic lethal relationship. Sci
Transl Med 2014;6:237ra68. DOI PubMed PMC
106. Miyanaga A, Masuda M, Tsuta K, et al. Hippo pathway gene mutations in malignant mesothelioma: revealed by RNA and targeted
exon sequencing. J Thorac Oncol 2015;10:844-51. DOI
107. Sato T, Sekido Y. NF2/Merlin inactivation and potential therapeutic targets in mesothelioma. Int J Mol Sci 2018;19:988. DOI
PubMed PMC
108. Zhang WQ, Dai YY, Hsu PC, et al. Targeting YAP in malignant pleural mesothelioma. J Cell Mol Med 2017;21:2663-76. DOI
PubMed PMC
109. Cooper J, Xu Q, Zhou L, et al. Combined inhibition of NEDD8-activating enzyme and mTOR suppresses NF2 loss-driven
tumorigenesis. Mol Cancer Ther 2017;16:1693-704. DOI PubMed PMC
110. Fennell DA, Baas P, Taylor P, et al. Maintenance defactinib versus placebo after first-line chemotherapy in patients with merlin-